Atrial Fibrillation History Impact on Catheter Ablation Outcome

Pacing and Clinical ElectrophysiologyVolume 42, Issue 6 p. 759-759 LETTER TO EDITOR - RESPONSE Atrial fibrillation history impact on catheter ablation outcome Giuseppe Stabile MD, Corresponding Author Giuseppe Stabile MD gmrstabile@tin.it orcid.org/0000-0003-4646-0865 Department of Electrophysiology, Clinica Montevergine, Mercogliano, Italy Department of Electrophysiology, Clinica San Michele, Maddaloni, Italy Correspondence Giuseppe Stabile, Laboratorio di Elettrofisiologia, Clinica San Michele, Via Montella 16, Maddaloni, Italy. Email: gmrstabile@tin.itSearch for more papers by this authorSerge A. Trines MD, Serge A. Trines MD Heart Lung Centre, Leiden University Medical Centre, Leiden, The NetherlandsSearch for more papers by this authorCarina Blomström Lundqvist MD, Carina Blomström Lundqvist MD Department of Cardiology and Medical Science, Uppsala University, Uppsala, SwedenSearch for more papers by this authoron behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators, on behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigatorsSearch for more papers by this author Giuseppe Stabile MD, Corresponding Author Giuseppe Stabile MD gmrstabile@tin.it orcid.org/0000-0003-4646-0865 Department of Electrophysiology, Clinica Montevergine, Mercogliano, Italy Department of Electrophysiology, Clinica San Michele, Maddaloni, Italy Correspondence Giuseppe Stabile, Laboratorio di Elettrofisiologia, Clinica San Michele, Via Montella 16, Maddaloni, Italy. Email: gmrstabile@tin.itSearch for more papers by this authorSerge A. Trines MD, Serge A. Trines MD Heart Lung Centre, Leiden University Medical Centre, Leiden, The NetherlandsSearch for more papers by this authorCarina Blomström Lundqvist MD, Carina Blomström Lundqvist MD Department of Cardiology and Medical Science, Uppsala University, Uppsala, SwedenSearch for more papers by this authoron behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators, on behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigatorsSearch for more papers by this author First published: 04 March 2019 https://doi.org/10.1111/pace.13645 Funding information: Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011-2014), Amgen Cardiovascular (2009-2018), AstraZeneca (2014-2017), Bayer AG (2009-2018), Boehringer Ingelheim (2009-2019), Boston Scientific (2009-2012), The Bristol Myers Squibb and Pfizer Alliance (2011-2019), Daiichi Sankyo Europe GmbH (2011-2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014-2017), Edwards (2016-2019), Gedeon Richter Plc. (2014-2016), Menarini Int. Op. (2009-2012), MSD-Merck & Co. (2011-2014), Novartis Pharma AG (2014-2017), ResMed (20142016), Sanofi (2009-2011), and SERVIER (2009-2018). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume42, Issue6June 2019Pages 759-759 RelatedInformation